BLRX — BioLineRx Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1498403 ·
Israel
Last close
$2.43
Market Cap
$11.78M
52W High
$4.56
52W Low
$2.15
ADV30
22,487
Next earnings
2026-11-23
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 294,000 | 235,000 | -3,573,000 | -3,026,000 | 33,480,000 | 4,627,000 | 16,861,000 |
| Mar 2026 | 477,000 | 382,000 | -3,004,000 | -1,601,000 | 38,797,000 | 2,504,000 | 17,962,000 |
| Dec 2025 | 194,000 | 154,000 | -3,386,000 | -1,385,000 | 40,905,000 | 3,250,000 | 17,560,000 |
| Sep 2025 | 427,000 | 343,000 | -2,207,000 | -977,000 | 39,804,000 | 7,914,000 | 20,271,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,763,000
Investing CF
$2,335,000
Financing CF
$-1,746,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-402,603,000
Inventory
$2,157,000
Receivables
$1,891,000
ST Investments
$14,849,000
EBIT TTM
$-8,660,000
Pretax Income TTM
$-9,741,000
Interest Exp TTM
$1,081,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,392,000
EBITDA
$-12,118,000
Free Cash Flow
$-8,852,375
Enterprise Value
$8,676,421
Total Cash
$13,078,000
Total Debt
$7,941,000
Shares Out
4,848,991
Trailing EPS
$0.00
Book Value
$3.00
ROE
-55.3%
ROA
-19.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,180,000 | -10,287,000 | -1,175,000 | 40,905,000 | 17,560,000 | 18,196,000 | -8,074,000 |
| Dec 2024 | 28,940,000 | -19,152,000 | -9,221,000 | 38,906,000 | 25,445,000 | 13,461,000 | -43,873,000 |
| Dec 2023 | 4,800,000 | -42,991,000 | -60,614,000 | 63,925,000 | 50,702,000 | 13,223,000 | -22,608,000 |
| Dec 2022 | 0 | -29,157,000 | -24,951,000 | 76,384,000 | 25,543,000 | 50,841,000 | -26,240,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.52
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KPRX | KIORA PHARMACEUTICALS INC | $11.81M | $2.67 | — |
| PHIO | Phio Pharmaceuticals Corp. | $11.73M | $1.01 | — |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $11.85M | $4.04 | — |
| ASBP | Aspire Biopharma Holdings, Inc. | $11.92M | $8.50 | — |
| CMMB | Chemomab Therapeutics Ltd. | $12.02M | $1.64 | — |
News headlines (Yahoo Finance, 1h cache)
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
2026-09-10 11:00 · Yahoo
BLRX: New GLIX1 Data Touts Synergies
2026-09-01 12:05 · Yahoo
BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ...
2026-08-31 21:00 · Yahoo
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-31 11:00 · Yahoo
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
2026-08-25 11:00 · Yahoo
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
2026-08-28 12:00 · Yahoo
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
2026-07-20 11:00 · Yahoo
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
2026-07-08 11:00 · Yahoo
BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
2026-06-03 01:01 · Yahoo
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-27 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.